7,9-dimethyl-7,9-dihydro-purin-8-one | 101861-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 7,9-dimethyl-7,9-dihydro-purin-8-one
• 英文别名: 7,9-Dimethyl-7,9-dihydro-purin-8-on；Purine, 7,8-dihydro-7,9-dimethyl-8-oxo-；7,9-dimethylpurin-8-one
• CAS: 101861-09-0
• 化学式: C₇H₈N₄O
• 分子量: 164.167
• InChiKey: XUJHLVLIGDUYDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  49.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,6-dichloro-7,9-dimethyl-7,9-dihydro-purin-8-one 在 phosphonium iodide 、 氢碘酸 作用下， 生成 7,9-dimethyl-7,9-dihydro-purin-8-one
  参考文献：
  名称：

  Fischer,E., Chemische Berichte, 1884, vol. 17, p. 333

  摘要：

  DOI：

文献信息

• Heterocyclic compounds as inhibitors of class I PI3KS
  申请人：Ruan Fuqiang

  公开号：US20160222012A1

  公开（公告）日：2016-08-04

  The present application discloses a novel class of heterocycles as class I PI3Ks inhibitors. The compounds claimed herein could be used alone or in combination therapies for the treatment of a wide range of disorders such as autoimmune, inflammatory and allergic diseases, asthma, COPD, parasitic infections, diabetes, and cancer.

  本申请公开了一类新型的杂环化合物，作为I类PI3K抑制剂。本文所声称的化合物可单独使用，也可与其他疗法结合治疗多种疾病，如自身免疫性、炎症性和过敏性疾病、哮喘、慢性阻塞性肺疾病、寄生虫感染、糖尿病和癌症。
• ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, COMPOSITION FOR CHARGE-TRANSPORTING MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE
  申请人：IIDA Koichiro

  公开号：US20090284134A1

  公开（公告）日：2009-11-19

  An organic compound having excellent heat resistance, an excellent amorphous nature, an excellent ability to transport charges, highly excited singlet and triplet states, and excellent solubility in an organic solvent is an organic compound represented by Formula (I): wherein Ar 1 represents an optionally-substituted aromatic hydrocarbon group, an optionally-substituted aromatic heterocyclic group, or an optionally-substituted alkyl group; Ar 2 represents an optionally-substituted aromatic hydrocarbon group or an optionally-substituted aromatic heterocyclic group; R 1 and R 2 each represent a hydrogen atom or a substituent, and R 1 and R 2 may be bonded to each other to form a ring; and Q is represented by Formula (I-1) or (I-2): wherein Ar 3 to Ar 5 each represent an optionally-substituted aromatic hydrocarbon group or an optionally-substituted aromatic heterocyclic group, and Ar 3 and Ar 4 may be bonded to each other to form a ring.

  具有优异热稳定性、优异非晶性、优异电荷传输能力、高度激发单重态和三重态状态、以及在有机溶剂中优异溶解性的有机化合物，可以用公式（I）表示，其中Ar1代表可选取代的芳香烃基、可选取代的芳香杂环基或可选取代的烷基；Ar2代表可选取代的芳香烃基或可选取代的芳香杂环基；R1和R2分别代表氢原子或取代基，R1和R2可相互连接形成环；Q由公式（I-1）或（I-2）表示，其中Ar3至Ar5分别代表可选取代的芳香烃基或可选取代的芳香杂环基，Ar3和Ar4可相互连接形成环。
• [EN] HETEROCYCLIC ARYL FORMAMIDES OR SALT THEREOF, PREPARATION METHOD, WEEDING COMPOSITION, AND APPLICATION<br/>[FR] FORMAMIDES D'ARYLE HÉTÉROCYCLIQUES OU SEL DE CEUX-CI, PROCÉDÉ DE PRÉPARATION, COMPOSITION DE DÉSHERBAGE ET UTILISATION<br/>[ZH] 杂环基芳基甲酰胺类或其盐、制备方法、除草组合物和应用
  申请人：QINGDAO KINGAGROOT CHEMICAL COMPOUND CO LTD

  公开号：WO2020156106A1

  公开（公告）日：2020-08-06

  一种杂环基芳基甲酰胺类或其盐、制备方法、除草组合物和应用。所述杂环基芳基甲酰胺类化合物或其盐的结构式如式I，化合物的除草活性优异，且具有更高的作物安全性，尤其是对于小麦、水稻、玉米等关键农作物建立了良好的选择性。
• HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20180002343A1

  公开（公告）日：2018-01-04

  The invention provides compounds that inhibit monocarboxylate transporters, such as MCT1 and MCT4. Compounds of the invention can be used for treatment of a condition in a patient, wherein the condition is characterized by the heightened activity or by the high prevalence of MCT1 and/or MCT4, such as cancer or type II diabetes.
• PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20180008605A1

  公开（公告）日：2018-01-11

  The invention provides compounds effective as inhibitors of monocarboxylate transporters such as MCT1 and MCT4, which can be used for treatment of medical conditions wherein treatment of the condition with a compound having an inhibitor effect on MCT1, MCT4, or both is medically indicated. Compounds of the invention can have antitumor, antidiabetes, anti-inflammatory, or immunosuppressive pharmacological effects, and can be effective for treatment of cancer and of type II diabetes.